杭州昊鑫生物科技股份有限公司
標(biāo)準(zhǔn)會(huì)員 | 第3年

當(dāng)前位置:杭州昊鑫生物科技股份有限公司>>MCE>> HY-10997Ibrutinib (伊布替尼)

Ibrutinib (伊布替尼)

參  考  價(jià):600
具體成交價(jià)以合同協(xié)議為準(zhǔn)
  • 型號(hào)

    HY-10997

  • 品牌

    MCE

  • 廠商性質(zhì)

    代理商

  • 所在地

    杭州市

規(guī)格

5mg 600元 10000支可售

聯(lián)系方式:鄧女士查看聯(lián)系方式

更新時(shí)間:2024-06-24 11:50:15瀏覽次數(shù):118次

聯(lián)系我時(shí),請(qǐng)告知來(lái)自 制藥網(wǎng)
同類優(yōu)質(zhì)產(chǎn)品更多>
產(chǎn)地 國(guó)產(chǎn) 規(guī)格 5mg
級(jí)別 化工級(jí) 證書(shū) ISO系列證書(shū)
Ibrutinib (PCI-32765) 是一種不可逆的選擇性 Btk 抑制劑,IC50 值為 0.5 nM。Ibrutinib 可作為 Btk 配體,用于合成一系列 PROTAC 分子,如 P13I。P13I 作用于人 Burkitt’s 淋巴瘤 RAMOS 細(xì)胞,濃度為 10 和 100?nM 時(shí),分別降解 73% 和 89% Btk。

Ibrutinib  (Synonyms: 伊布替尼; PCI-32765)

Ibrutinib (PCI-32765) 是一種不可逆的選擇性 Btk 抑制劑,IC50 值為 0.5 nM。Ibrutinib 可作為 Btk 配體,用于合成一系列 PROTAC 分子,如 P13I。P13I 作用于人 Burkitt’s 淋巴瘤 RAMOS 細(xì)胞,濃度為 10 和 100?nM 時(shí),分別降解 73% 和 89% Btk。

生物活性

Ibrutinib (PCI-32765) is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM[1].


IC50 & Target

IC50: 0.5 nM (Btk)


體外研究(In Vitro)

Ibrutinib (PCI-32765) selectively inhibits B-cell signaling and activation. It inhibits autophosphorylation of Btk (IC50=11 nM), phosphorylation of Btk's physiological substrate PLCγ (IC50=29 nM), and phosphorylation of a further downstream kinase, ERK (IC50=13 nM)[1].
Ibrutinib (PCI-32765) inhibits BCR-activated primary B cell proliferation (IC50=8 nM). Following FcγR stimulation, Ibrutinib (PCI-32765) inhibits TNFα, IL-1β and IL-6 production in primary monocytes (IC50=2.6, 0.5, 3.9 nM, respectively)[3].
Ibrutinib binds C481 (Cysteine481) of BTK with an ideal IC50 of 0.5?nM. Ibrutinib cannot form a covalent bond with the hydroxyl group of serine, C481S mutation increases the IC50 against BTK-C481S phosphorylation from 2.2?nM to 1?μM[4].


體內(nèi)研究(In Vivo)

Ibrutinib (PCI-32765) (3.125-50 mg/kg, p.o.) reduces the level of circulating autoantibodies and completely suppresses disease in mice with collagen-induced arthritis. Ibrutinib (PCI-32765) inhibits autoantibody production and the development of kidney disease in the MRL-Fas(lpr) lupus model. Ibrutinib (PCI-32765) (3.125-50 mg/kg, p.o.) reduces renal disease and autoantibody production in MRL-Fas(lpr) mice[1]. Ibrutinib (PCI-32765) (0.1 μM) inhibits activation-induced proliferation of CLL cells, induces selective cytotoxicity in B cells compared with T cells, but alters activation induced T-cell cytokine production[2]. Ibrutinib (PCI-32765) dose-dependently and potently reverses arthritic inflammation in a therapeutic CIA model with an ED50 of 2.6 mg/kg/day. Ibrutinib (PCI-32765) also prevents clinical arthritis in CAIA models[3].


分子量:440.50


性狀:Solid


Formula:C25H24N6O2


CAS 號(hào):936563-96-1


中文名稱:依魯替尼;伊布魯替尼;伊布替尼


運(yùn)輸條件:Room temperature in continental US; may vary elsewhere.


儲(chǔ)存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)


溶解性數(shù)據(jù)


In Vitro:

DMSO : 100 mg/mL (227.01 mM; Need ultrasonic)

配制儲(chǔ)備液
濃度溶劑體積質(zhì)量1 mg5 mg10 mg
1 mM2.2701 mL11.3507 mL22.7015 mL
5 mM0.4540 mL2.2701 mL4.5403 mL
10 mM0.2270 mL1.1351 mL2.2701 mL
*

請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?6 個(gè)月內(nèi)使用,-20°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?1 個(gè)月內(nèi)使用。

In Vivo:

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:

——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用; 以下溶劑前顯示的百
分比是指該溶劑在您配制終溶液中的體積占比;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶

  • 1.


    請(qǐng)依序添加每種溶劑: 0.5% MC 0.5% Tween-80

    Solubility: 3.33 mg/mL (7.56 mM); Suspension solution; Need ultrasonic


  • 2.


    請(qǐng)依序添加每種溶劑: 5% DMSO    95% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.75 mg/mL (6.24 mM); Clear solution


  • 3.


    請(qǐng)依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.68 mM); Clear solution


  • 4.


    請(qǐng)依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (5.68 mM); Suspended solution; Need ultrasonic


  • 5.


    請(qǐng)依序添加每種溶劑: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.68 mM); Clear solution


參考文獻(xiàn)

[1]. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.  [Content Brief]

[2]. Herman SE, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011 Jun 9;117(23):6287-96.  [Content Brief]

[3]. Chang BY, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13;13(4):R115.  [Content Brief]

[4]. Sun Y, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 2018 Jul;28(7):779-781.  [Content Brief]



會(huì)員登錄

×

請(qǐng)輸入賬號(hào)

請(qǐng)輸入密碼

=

請(qǐng)輸驗(yàn)證碼

收藏該商鋪

X
該信息已收藏!
標(biāo)簽:
保存成功

(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時(shí)間回復(fù)您~
在線留言